Adempas: first soluble guanylate cyclase stimulator for pulmonary hypertension

Bayer has launched the first-in-class treatment Adempas (riociguat) to improve exercise capacity in adults with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Adempas (riociguat) provides a new treatment option for patient with pulmonary hypertension (pictured) | SCIENCE PHOTO LIBRARY
Adempas (riociguat) provides a new treatment option for patient with pulmonary hypertension (pictured) | SCIENCE PHOTO LIBRARY


Riociguat is a soluble guanylate cyclase (sGC) stimulator which has a dual mechanism of action. It sensitises sGC to endogenous nitric oxide (NO) by stabilising binding between sGC and NO and directly stimulates sGC independently of NO.


Riociguat has been studied in two key phase III clinical trials. The PATENT-1 study evaluated riociguat in patients with symptomatic pulmonary arterial hypertension and the CHEST-1 study assessed the efficacy and safety of riociguat for the treatment of chronic thromboembolic pulmonary hypertension that was inoperable or that had persisted or recurred after pulmonary endartectomy.

In both trials, patients were randomised to receive placebo or riociguat titrated over 8 weeks to optimal individual dose (range 500 microgram to 2.5mg three times daily), which was then maintained over a further 4 weeks in PATENT-1 and 8 weeks in CHEST-1. 

The primary endpoint, placebo-adjusted change from baseline in 6-minute walk distance, was 36 metres in PATENT-1 and 46 metres in CHEST-1 (p<0.0001 for both comparisons).

Headache, hypotension, GI upset, dizziness and peripheral oedema were the most commonly reported adverse effects.

View Adempas drug record

Further information: Bayer

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases